ZEGALOGUE
Peakdasiglucagon
NDASUBCUTANEOUSSOLUTION
Approved
Mar 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Mechanism of Action
Glucagon Receptor Agonists
Pharmacologic Class:
Antihypoglycemic Agent
Clinical Trials (2)
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
Started Sep 2024
38 enrolled
Diabetes Mellitus, Type 1
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
Started May 2023
8 enrolled
HypoglycemiaType 1 Diabetes
Loss of Exclusivity
LOE Date
Feb 3, 2035
108 months away
Patent Expiry
Feb 3, 2035
Exclusivity Expiry
Mar 22, 2026